Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 185 participants.
Also called NCT02947620
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 185 participants
- Registry
-
NCT02947620
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02947620. Randomized; double masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2017-02-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
- Condition
- Type II Diabetes
- Condition
- Dyslipidemia
- Intervention (Drug)
- Metformin/Atorvastatin 1500mg/40mg, QD
- Intervention (Drug)
- Metformin 1500mg, QD
- Intervention (Drug)
- Atorvastatin 40mg, QD
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct02947620- Content hash
cd2f12c3e315833a04ad3fc783b8a55cbf1804b1b0597dbc27be48771c1acb4d